Virological Success With Long-Acting Cabotegravir and Rilpivirine Despite Historical Rilpivirine Resistance: A Real-World Case Series

In a case series of 13 individuals with historical rilpivirine (RPV) resistance-associated mutations, predominantly E138A, long-acting cabotegravir/rilpivirine (CAB/RPV) maintained suppression over a median 24-month follow-up. Twelve were virologically suppressed at switch. No virological failures occurred, supporting cautious CAB/RPV use in selected patients with remote or polymorphic mutations.